MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- INDRAPRASTHA MEDICAL
INDRAPRASTHA MEDICAL Share Price (IRMED)
Here is the latest stock price and chart of INDRAPRASTHA MEDICAL. For more details, see the INDRAPRASTHA MEDICAL company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
LIVE NOW!: Equitymaster's Biggest Wealth Creating Project Ever is LIVE. Watch Now!
| Live BSE Quotes | Feb 25, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)41.60 | Open (Rs) 41.90 | High (Rs) 42.15 | Low (Rs) 41.45 |
| % Change-0.12 | Volume 13,530 | Value (Rs) 567,408 | 52-Week H/L 52.40 / 33.80 |
| Live NSE Quotes | Feb 25, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)41.65 | Open (Rs) 41.40 | High (Rs) 42.15 | Low (Rs) 41.40 |
| % Change-0.12 | Volume 42,216 | Value (Rs) 1,762,067 | 52-Week H/L 52.50 / 35.10 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 4.44 | P/E Ratio (x) 9.37 | Market Cap (Rs m) 3,813.47 | P/BV (x) 1.56 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
INDRAPRASTHA MEDICAL Share Price Today:
INDRAPRASTHA MEDICAL last traded price was down 0.1% to Rs 41.6 on the BSE. On the NSE, INDRAPRASTHA MEDICAL last traded price was down 0.1% to Rs 41.7. The total volume of shares traded was 0.1 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.2%. And the benchmark S&P BSE SENSEX was at 40,281.2 (down 0.2%).
Over the last 30 days, the INDRAPRASTHA MEDICAL share price is down 9.7%. And over the last one year, INDRAPRASTHA MEDICAL share price is up 12.0%.
Today's Market
Sensex Extends Slide, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)
On Tuesday, Indian share markets witnessed volatile trading activity throughout the day and ended marginally lower.
Related Views On News
INDRAPRASTHA MEDICAL Announces Quarterly Results (2QFY20); Net Profit Up 133.6% (Quarterly Result Update)
Nov 8, 2019 | Updated on Nov 8, 2019For the quarter ended September 2019, INDRAPRASTHA MEDICAL has posted a net profit of Rs 179 m (up 133.6% YoY). Sales on the other hand came in at Rs 2 bn (up 8.0% YoY). Read on for a complete analysis of INDRAPRASTHA MEDICAL's quarterly results.
INDRAPRASTHA MEDICAL 2018-19 Annual Report Analysis (Annual Result Update)
Oct 18, 2019 | Updated on Oct 18, 2019Here's an analysis of the annual report of INDRAPRASTHA MEDICAL for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of INDRAPRASTHA MEDICAL. Also includes updates on the valuation of INDRAPRASTHA MEDICAL.
INDRAPRASTHA MEDICAL Announces Quarterly Results (1QFY20); Net Profit Up 31.5% (Quarterly Result Update)
Jul 29, 2019 | Updated on Jul 29, 2019For the quarter ended June 2019, INDRAPRASTHA MEDICAL has posted a net profit of Rs 85 m (up 31.5% YoY). Sales on the other hand came in at Rs 2 bn (up 7.6% YoY). Read on for a complete analysis of INDRAPRASTHA MEDICAL's quarterly results.
More Views on NewsMost Popular
The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks (Profit Hunter)
Feb 19, 2020While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.
Here's Why I Recommended 15 Stocks in One Day Flat 
(Views On News)
Feb 14, 2020
This proven strategy can give big returns in quick time.
The Top 8 Trading Mistakes You Should Avoid (Fast Profits Daily)
Feb 18, 2020Avoid these mistakes and your trading will turn much more profitable.
Corona Virus Could Trigger a Rally in this Stock (Profit Hunter)
Feb 20, 2020A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.
These Rebirth of India Stocks Are Raring to Compete with Tesla (The 5 Minute Wrapup)
Feb 17, 2020There are Indian stocks which can soar like Tesla in the long-run.
MoreOUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- LIVE NOW!: Equitymaster's Biggest Wealth Creating Project Ever is LIVE. Watch Now!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK INDRAPRASTHA MEDICAL
- Track your investment in INDRAPRASTHA MEDICAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON INDRAPRASTHA MEDICAL
INDRAPRASTHA MEDICAL 5-YR ANALYSIS
COMPARE INDRAPRASTHA MEDICAL WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.